• Parasites, Hosts and Diseases
• /
• 제33권4호
• /
• pp.377-382
• /
• 1995

Cryptosporidium muris(strain MCR)를 3주령의 각 마우스에 $2{\;}\times{\;}10^6$개의 오오시스트차 그 10 배 단계 희석계열을 $2{\;}{\times}{\;}10^5$까지 5단계를 만들어 경구접종하여 오오시스트 배설g/100g을 조사하고 나서 초감염내과 마우스에 처음에 50 mg/100g. 그 24시간 후에 12.5 mg/100 g의 carrageenan을 복강내 투여하고 그 6시간 후에 다시 $2{\;}\times{\;}10^6$개의 오오시스트를 2차접종하여 면역원성을 조사하였다 일반적으로 오오시스트 투여량이 많을수록 오오시스트 배설량이 많았으나 prepatent period(9-11일간)와 오오시스트 생산이 피이크에 이르는 기간(16-36일간)은 짧았다. Patent period는 61-64일간이었으며 15-31일간에 걸쳐 오오시스트가 많이 생산되었다. 한편 IgG 항체가의 현저한 상승과 분변내 오오시스트 소멸은 일치하였다 Carrageenan 투여군은 오오시스트 재차접종 후 16 0-18.0(16.6)일부터 61-66.5(64.8)일까지 46.0-51.5(49.0)일간 대조군은 15.5-17.5(16.4)일부터 29.0-31.0(29.8)일까지 12.0-16.0(14.2)일간에 걸쳐 소수의 오오시스트가 검출되었다. 재차접종 직전의 말초혈액내 대식세포수 및 복강내 대식세포 활성은 대조군에 비하여 carrageenan 투여군이 현저하게 낮았다(P < 0.05). 이는 Me blocker인 carrageenan을 투여하였음에도 불구하고 이 원충의 2차감염이 미약하였다는 것은 이 원충의 면역원성이 매우 강력하다는 것을 뜻한다.

• Journal of Microbiology and Biotechnology
• /
• 제15권4호
• /
• pp.909-912
• /
• 2005

In the course of screening for selective growth inhibitors against the mycelial form of Candida albicans, we isolated a Streptomyces sp. A6792 from soils. The inhibitor was isolated from the above bacterium and identified through several spectral analyses with UV and mass spectrophotometries, and various NMR. The compound was determined to be a macrocyclic dilactone antibiotic, IKD-8344 (molecular weight: 844, molecular formula: $C_{48}H_{76}O_{12}$). The compound selectively inhibited the growth of mycelial form of C. albicans with an MIC of 6.25 ${\mu}g/ml$. It also exhibited strong inhibitory effect preferentially on the mycelial form of various Candida spp. including C. krusei, C. tropicalis, and C. lusitaniae, with MICs ranging from 1.56 to 25 ${\mu}g$/ml. Furthermore, the compound showed no significant toxicity against SPF ICR mice up to 60 mg/kg. These results suggest that IKD-8344 is a useful lead compound for the development of novel antifungal agents, based on the preferential growth inhibition against Candida spp.

• Biomolecules & Therapeutics
• /
• 제10권4호
• /
• pp.268-273
• /
• 2002

Mutagenic potential of HM10411 (recombinant human granulocyte colony stimulating factor) was evaluated by bacterial reverse mutation test, in vitro chromosome aberration test and in vivo micronucleus test. The bacterial reverse mutation test was performed using the histidine auxotroph strains of Salmonella typhimurium TA100, TA1535, TA98, TA1537 and tryptophan auxotroph strain of Escherichia coli WP2 uvrA. The negative results of the bacterial reverse mutation test suggest that HM10411 does not induce mutation, in the genome of Salmonella typhimurium and E. coli under the conditions used. In addition, it has little clastogenicity either in vitro chromosome aberration test or in vivo micronucleus test. For in vitro chromosomal aberration test, Chinese hamster lung(CHL) cells were exposed to HM10411 of 23, 46 or 92 $\mu\textrm{g}$/ml for 6 or 24 hours in the absence and for 6 hours in the presence of metabolic activation system. There was no significant increase in the number of aberrant metaphase in HM 10411-treated groups at any dose levels both in the presence and absence of metabolic activation system. The micronucleus test was carried out using specific pathogen free(SPF) 7-week old male ICR mice, The test item, HM10411 was intraperitoneally administered at 1150, 2300 or 4600 $\mu\textrm{g}$/kg once a day for 2 consecutive days. There was no significant increase in the frequencies of micronucleated polychromatic erythrocytes(PCEs) at any treated groups compared with negative control group. Therefore, these results demonstrate that the test item, HM10411, was not mutagenic under the condition of these studies.